GoodRx (GDRX)
Market Price (5/11/2026): $2.915 | Market Cap: $992.6 MilSector: Health Care | Industry: Health Care Technology
GoodRx (GDRX)
Market Price (5/11/2026): $2.915Market Cap: $992.6 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% Attractive yieldFCF Yield is 9.7% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and E-commerce & Digital Retail. Themes include Telehealth Platforms, Health Data Analytics, Show more. | Weak multi-year price returns2Y Excs Rtn is -103%, 3Y Excs Rtn is -114% | Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 48x Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.2%, Rev Chg QQuarterly Revenue Change % is -4.4% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.3% Key risksGDRX key risks include [1] regulatory enforcement and lawsuits related to data sharing and anticompetitive practices, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Attractive yieldFCF Yield is 9.7% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and E-commerce & Digital Retail. Themes include Telehealth Platforms, Health Data Analytics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -103%, 3Y Excs Rtn is -114% |
| Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 48x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.2%, Rev Chg QQuarterly Revenue Change % is -4.4% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.3% |
| Key risksGDRX key risks include [1] regulatory enforcement and lawsuits related to data sharing and anticompetitive practices, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Strong Q1 2026 Financial Results Exceeded Expectations and Upgraded Full-Year Guidance.
GoodRx reported first-quarter 2026 revenue of $194 million, surpassing analyst estimates by 5.1%, and adjusted EBITDA of $58.3 million, beating estimates by 3.8%. The company also raised its full-year 2026 revenue guidance to a range of $765 million to $785 million and adjusted EBITDA to at least $235 million.
2. Exceptional Growth in the Pharma Direct Segment.
The Pharma Direct revenue segment surged 82% year-over-year to $52.2 million. This growth was driven by expanded partnerships with pharmaceutical manufacturers, including new collaborations with Viatris for 17 brand medications and Pfizer for over 30 essential medications. GoodRx also accounted for approximately one-third of early Wegovy Pill transactions.
Show more
Stock Movement Drivers
Fundamental Drivers
The 28.6% change in GDRX stock from 1/31/2026 to 5/10/2026 was primarily driven by a 95.1% change in the company's P/E Multiple.| (LTM values as of) | 1312026 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.27 | 2.92 | 28.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 801 | 788 | -1.6% |
| Net Income Margin (%) | 4.0% | 2.6% | -34.2% |
| P/E Multiple | 24.8 | 48.4 | 95.1% |
| Shares Outstanding (Mil) | 347 | 341 | 1.8% |
| Cumulative Contribution | 28.6% |
Market Drivers
1/31/2026 to 5/10/2026| Return | Correlation | |
|---|---|---|
| GDRX | 28.6% | |
| Market (SPY) | 3.6% | 39.5% |
| Sector (XLV) | -6.9% | 4.1% |
Fundamental Drivers
The -13.4% change in GDRX stock from 10/31/2025 to 5/10/2026 was primarily driven by a -39.7% change in the company's Net Income Margin (%).| (LTM values as of) | 10312025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.37 | 2.92 | -13.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 800 | 788 | -1.5% |
| Net Income Margin (%) | 4.3% | 2.6% | -39.7% |
| P/E Multiple | 34.7 | 48.4 | 39.3% |
| Shares Outstanding (Mil) | 357 | 341 | 4.7% |
| Cumulative Contribution | -13.4% |
Market Drivers
10/31/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| GDRX | -13.4% | |
| Market (SPY) | 5.5% | 36.8% |
| Sector (XLV) | 0.3% | 7.5% |
Fundamental Drivers
The -36.9% change in GDRX stock from 4/30/2025 to 5/10/2026 was primarily driven by a -55.7% change in the company's P/E Multiple.| (LTM values as of) | 4302025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.63 | 2.92 | -36.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 792 | 788 | -0.6% |
| Net Income Margin (%) | 2.1% | 2.6% | 26.1% |
| P/E Multiple | 109.1 | 48.4 | -55.7% |
| Shares Outstanding (Mil) | 386 | 341 | 13.4% |
| Cumulative Contribution | -36.9% |
Market Drivers
4/30/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| GDRX | -36.9% | |
| Market (SPY) | 30.4% | 27.6% |
| Sector (XLV) | 4.0% | 17.8% |
Fundamental Drivers
The -37.5% change in GDRX stock from 4/30/2023 to 5/10/2026 was primarily driven by a -49.7% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.67 | 2.92 | -37.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 767 | 788 | 2.8% |
| P/S Multiple | 2.5 | 1.3 | -49.7% |
| Shares Outstanding (Mil) | 412 | 341 | 20.9% |
| Cumulative Contribution | -37.5% |
Market Drivers
4/30/2023 to 5/10/2026| Return | Correlation | |
|---|---|---|
| GDRX | -37.5% | |
| Market (SPY) | 78.7% | 30.6% |
| Sector (XLV) | 13.0% | 17.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GDRX Return | -19% | -86% | 44% | -31% | -42% | 5% | -93% |
| Peers Return | 12% | -1% | 20% | 33% | 18% | 5% | 120% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 95% |
Monthly Win Rates [3] | |||||||
| GDRX Win Rate | 42% | 33% | 58% | 25% | 33% | 60% | |
| Peers Win Rate | 48% | 50% | 50% | 55% | 53% | 48% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| GDRX Max Drawdown | -30% | -88% | -6% | -38% | -44% | -31% | |
| Peers Max Drawdown | -17% | -26% | -16% | -16% | -18% | -21% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: HIMS, AMZN, CVS, UNH, CI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)
How Low Can It Go
| Event | GDRX | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -15.1% | -7.8% |
| % Gain to Breakeven | 17.8% | 8.5% |
| Time to Breakeven | 11 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -32.9% | -9.5% |
| % Gain to Breakeven | 49.1% | 10.5% |
| Time to Breakeven | 50 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -17.0% | -6.7% |
| % Gain to Breakeven | 20.4% | 7.1% |
| Time to Breakeven | 14 days | 31 days |
In The Past
GoodRx's stock fell -15.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 17.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | GDRX | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -32.9% | -9.5% |
| % Gain to Breakeven | 49.1% | 10.5% |
| Time to Breakeven | 50 days | 24 days |
In The Past
GoodRx's stock fell -15.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 17.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About GoodRx (GDRX)
AI Analysis | Feedback
- Kayak for prescription drugs
- Zillow for prescription drug prices
- Honey for prescription drugs
AI Analysis | Feedback
GoodRx's major products and services include:
- Prescription Savings Platform: A digital platform that enables consumers to compare prescription drug prices and access negotiated discounts using GoodRx codes.
- Subscription Services: Offers premium subscription plans that may provide additional savings or benefits to users.
- Pharma Manufacturer Solutions: Provides services to pharmaceutical manufacturers, likely related to patient access, adherence, or marketing.
- Telehealth Services: Offers virtual healthcare consultations and services to consumers.
AI Analysis | Feedback
GoodRx (GDRX) primarily sells its services to other companies. Its major customers fall into the following categories:
- Pharmacy Benefit Managers (PBMs): GoodRx partners with Pharmacy Benefit Managers, who pay GoodRx transaction fees when consumers utilize GoodRx codes to save money on prescription drug purchases. These PBMs manage formularies and prescription transactions between consumers and pharmacies.
- Pharmaceutical Manufacturers: GoodRx offers solutions to pharmaceutical manufacturers, which include programs designed to help patients access and afford their medications.
AI Analysis | Feedback
```html- CVS Health (CVS)
- Cigna (CI)
- UnitedHealth Group (UNH)
- Prime Therapeutics
AI Analysis | Feedback
Wendy Barnes, Chief Executive Officer
Wendy Barnes was appointed Chief Executive Officer and President of GoodRx, effective January 1, 2025. Prior to joining GoodRx, she served as the Chief Executive Officer of RxBenefits, Inc., a pharmacy benefits optimizer. She also held various roles at Express Scripts Holding Company, including President of Express Scripts Pharmacy, overseeing service, operations, and financial success for millions of members. Additionally, Ms. Barnes served as Group Vice President at Rite Aid and held executive positions at Pfizer. She also dedicated 10 years as a Medical Service Corps Officer in the United States Air Force.
Christopher McGinnis, Chief Financial Officer & Treasurer
Christopher McGinnis was appointed Chief Financial Officer of GoodRx in February 2025. He brings over 30 years of extensive financial leadership across the healthcare industry. Before joining GoodRx, Mr. McGinnis served as CEO of CitizensRx, a pharmacy benefits management provider, from 2021 to 2024. He previously held various executive roles at Lumeris/Essence Healthcare, a Medicare Advantage plan and value-based healthcare operator, including Chief Financial Officer and Executive Vice President of Operations. Earlier in his career, he was Chief Accounting Officer at Express Scripts Holding Company.
Trevor Bezdek, Co-founder and Co-Chair of the Board
Trevor Bezdek co-founded GoodRx in 2011. He served as Co-Chief Executive Officer and Secretary of the company from January 2015 to April 2023, transitioning to Chairman of the Board in April 2023, and later to Co-Chair. Prior to co-founding GoodRx, Mr. Bezdek was a Managing Partner at Tryarc, LLC, an information technology consulting firm, from 2001 to 2007. He also co-founded Biowire, a bioinformatics software provider.
Doug Hirsch, Co-founder and Director
Doug Hirsch co-founded GoodRx in 2011. He served as Co-Chief Executive Officer until April 2023, and is currently the Chief Mission Officer and a Director on the Board. Mr. Hirsch has a long history of building technology for consumers, having been among the first 30 employees at Yahoo!, where he created and managed early online communities such as GeoCities and Yahoo! Groups. He also served as Vice President of Product at Facebook in 2005. He founded DailyStrength, an online community for health challenges, which was acquired by HSW International in 2008. His personal experience with inconsistent prescription drug pricing was a key motivation for starting GoodRx.
Scott Wagner, Co-Chairman & Director
Scott Wagner has served as a member of GoodRx's board of directors since January 2025 and is a Co-Chairman. He previously held the role of Interim Chief Executive Officer from April 2023 to January 2025. Before joining GoodRx, Mr. Wagner held various executive roles at GoDaddy from 2012 to 2019, including Chief Executive Officer and President/Chief Financial Officer/Chief Operating Officer, where he helped triple the company's revenue to approximately $3 billion. From 2000 to 2012, he was a Partner at Kohlberg Kravis Roberts (KKR), a global private equity firm, indicating a pattern of managing companies backed by private equity firms.
AI Analysis | Feedback
Here are the key risks to GoodRx's business:
- Reliance on Pharmacy Benefit Managers (PBMs) and Pharmacy Relationships: GoodRx's business model is heavily dependent on its relationships with a limited number of Pharmacy Benefit Managers (PBMs) and large pharmacy chains. The high concentration within the PBM market, with a few major players processing a significant majority of prescription claims, gives these entities substantial market influence and negotiation power. This concentration can impact GoodRx's ability to negotiate drug prices and maintain its extensive network of pharmacies. Shifts in these relationships, renegotiations, or the introduction of new pricing frameworks by PBMs could directly undercut GoodRx's role and value proposition. GoodRx has also faced class-action lawsuits from independent pharmacies alleging conspiracy with PBMs to fix reimbursement rates.
- Regulatory and Policy Shifts, including Government-Sponsored Platforms: The highly regulated healthcare industry exposes GoodRx to significant risks from changes in laws and policies. New federal initiatives and policy shifts, such as government-sponsored platforms like "TrumpRx.gov," could directly compete with or significantly impact GoodRx's market position. The specific impact of such initiatives is often unclear but could be substantial. Additionally, evolving regulations concerning data privacy, telehealth services, and healthcare fraud and abuse require continuous adaptation and compliance, with any failure to comply potentially leading to significant repercussions. GoodRx previously faced an FTC enforcement action and a $1.5 million fine for improperly sharing health data, highlighting the ongoing regulatory scrutiny in this area.
- Intense Competition and Declining User Engagement: GoodRx operates in a highly competitive digital healthcare market, facing challenges from both established players and new entrants, including other prescription discount services and large pharmacy chains like Amazon Pharmacy. The company has experienced a decline in Monthly Active Consumers (MACs) and subscription revenue, partly due to the dynamic nature of the retail pharmacy sector, such as store closures (e.g., Rite Aid bankruptcy) and the discontinuation of partnerships (e.g., Kroger Savings Club). This decline in user engagement and strong competitive pressures pose ongoing challenges to GoodRx's market share and revenue growth.
AI Analysis | Feedback
The expansion of large technology companies (e.g., Amazon) into direct-to-consumer pharmacy services, offering simplified pricing structures or subscription models (such as Amazon RxPass), which could diminish the need for third-party prescription price comparison tools and discount codes for a significant portion of the market.
AI Analysis | Feedback
GoodRx Holdings, Inc. (GDRX) operates within several significant addressable markets in the United States for its main products and services:- Prescription Price Comparison Platform: The estimated total addressable market for the prescription opportunity, including prescriptions that are written but not filled, ranges from $515 billion to $588 billion in the U.S. This reflects the market for prescription drugs where consumers can find savings.
- Pharma Manufacturer Solutions: GoodRx estimates the addressable market for its pharma manufacturer solutions to be $19 billion in the U.S. Another estimate from the company states this market is over $7 billion. These solutions involve partnerships with pharmaceutical manufacturers to offer discounts and foster patient relationships.
- Telehealth Services: The company's IPO prospectus from 2020 estimated a telehealth opportunity of approximately $250 billion in the U.S. More broadly, the U.S. telehealth market was valued at approximately $42.54 billion in 2024 and is projected to reach $150.13 billion by 2030.
- Subscriptions: While GoodRx offers subscription services, such as GoodRx Gold, a specific addressable market size for these standalone subscription offerings is not separately quantified in the available information.
AI Analysis | Feedback
GoodRx (GDRX) is expected to drive future revenue growth over the next two to three years through several key initiatives:
- Growth in Pharma Manufacturer Solutions (Pharma Direct): GoodRx is strategically shifting its focus towards and expanding its Pharma Manufacturer Solutions, now branded as "Pharma Direct." This segment is consistently highlighted as a significant growth engine, with a reported 41% year-over-year growth in 2025 and an anticipated growth of at least 30% in 2026. This involves expanding direct-to-consumer affordability programs with pharmaceutical manufacturers.
- Expansion of Integrated Savings Program (ISP) and Organic Growth in Prescription Transactions: The company is experiencing organic growth in its prescription transactions revenue, partly due to the expansion of its Integrated Savings Program. This reflects GoodRx's continued ability to leverage its core price comparison platform and strengthen relationships with retail pharmacy partners.
- Differentiated Subscription Offerings: GoodRx is scaling its differentiated subscription offerings, particularly new condition-specific subscriptions, with weight loss subscriptions expected to contribute more significantly to revenue in 2026. Although subscription revenue experienced a temporary decline due to the sunset of the Kroger Savings Club, GoodRx Gold subscription plans have shown growth.
- GoodRx Employer Direct Offerings: GoodRx is entering the employer market by launching "GoodRx Employer Direct." This initiative aims to broaden access to prescription savings by integrating GoodRx's solutions into employer-sponsored benefit programs.
AI Analysis | Feedback
Share Repurchases
- In 2025, GoodRx repurchased 48.9 million shares of Class A common stock for an aggregate cost of $217.4 million.
- As of December 31, 2025, GoodRx had $72.9 million of unused authorized share repurchase capacity remaining under its $450.0 million share repurchase program, which does not have an expiration date.
- Significant share repurchases were also made in previous periods, including $154.85 million in Q1 2024 and $77.82 million in Q4 2023.
Capital Expenditures
- GoodRx reported capital expenditures of $74 million in 2025.
- Capital expenditures were approximately $70.35 million in 2024 and $55.77 million in 2023.
- A primary focus of GoodRx's capital allocation is investing for profitable growth.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| GoodRx Earnings Notes | 12/16/2025 | |
| GDRX: Strong Cash Flow at a Discounted Valuation? | 11/04/2025 | |
| How Low Can GoodRx Stock Really Go? | 10/17/2025 | |
| GoodRx (GDRX) Net Income Comparison | 08/08/2025 | |
| GoodRx (GDRX) Operating Income Comparison | 08/08/2025 | |
| GoodRx (GDRX) Operating Cash Flow Comparison | 08/08/2025 | |
| GoodRx (GDRX) Debt Comparison | 08/08/2025 | |
| GoodRx (GDRX) Tax Expense Comparison | 08/08/2025 | |
| GoodRx (GDRX) EBITDA Comparison | 08/08/2025 | |
| GoodRx (GDRX) Revenue Comparison | 08/08/2025 | |
| ARTICLES | ||
| Could GoodRx Stock’s Cash Flow Spark the Next Rally? | 11/04/2025 | |
| Market Movers | Winners: GDRX, DAY, OPEN | Losers: SLDP, KODK, CRK | 08/19/2025 |
Trade Ideas
Select ideas related to GDRX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -20.5% | -20.5% | -37.0% |
| 09302022 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 33.8% | 20.6% | -13.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 181.62 |
| Mkt Cap | 95.5 |
| Rev LTM | 342,872 |
| Op Inc LTM | 11,691 |
| FCF LTM | 3,745 |
| FCF 3Y Avg | 7,551 |
| CFO LTM | 9,572 |
| CFO 3Y Avg | 9,644 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.5% |
| Rev Chg 3Y Avg | 11.3% |
| Rev Chg Q | 5.6% |
| QoQ Delta Rev Chg LTM | 1.3% |
| Op Inc Chg LTM | 8.3% |
| Op Inc Chg 3Y Avg | -0.1% |
| Op Mgn LTM | 4.5% |
| Op Mgn 3Y Avg | 5.4% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 9.0% |
| CFO/Rev 3Y Avg | 9.0% |
| FCF/Rev LTM | 2.6% |
| FCF/Rev 3Y Avg | 4.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 95.5 |
| P/S | 1.0 |
| P/Op Inc | 18.3 |
| P/EBIT | 18.1 |
| P/E | 35.8 |
| P/CFO | 13.0 |
| Total Yield | 4.3% |
| Dividend Yield | 1.1% |
| FCF Yield 3Y Avg | 6.3% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 20.0% |
| 3M Rtn | 21.2% |
| 6M Rtn | 10.8% |
| 12M Rtn | -4.6% |
| 3Y Rtn | 32.3% |
| 1M Excs Rtn | 11.8% |
| 3M Excs Rtn | 14.5% |
| 6M Excs Rtn | 1.7% |
| 12M Excs Rtn | -37.5% |
| 3Y Excs Rtn | -46.4% |
Price Behavior
| Market Price | $2.92 | |
| Market Cap ($ Bil) | 1.0 | |
| First Trading Date | 09/23/2020 | |
| Distance from 52W High | -43.0% | |
| 50 Days | 200 Days | |
| DMA Price | $2.24 | $3.10 |
| DMA Trend | down | down |
| Distance from DMA | 30.4% | -5.8% |
| 3M | 1YR | |
| Volatility | 76.1% | 73.7% |
| Downside Capture | 1.07 | 1.08 |
| Upside Capture | 253.59 | 100.68 |
| Correlation (SPY) | 38.5% | 26.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.02 | 1.49 | 2.00 | 1.64 | 1.64 | 1.39 |
| Up Beta | 1.05 | -0.13 | 0.57 | 1.17 | 0.87 | 1.04 |
| Down Beta | 9.89 | 1.96 | 1.32 | 0.94 | 2.37 | 1.17 |
| Up Capture | 131% | 274% | 312% | 152% | 105% | 286% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 15 | 24 | 35 | 59 | 117 | 354 |
| Down Capture | -10% | 165% | 250% | 205% | 177% | 112% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 7 | 19 | 28 | 62 | 128 | 379 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GDRX | |
|---|---|---|---|---|
| GDRX | -17.9% | 74.2% | 0.03 | - |
| Sector ETF (XLV) | 7.9% | 15.4% | 0.30 | 16.9% |
| Equity (SPY) | 29.0% | 12.5% | 1.83 | 27.3% |
| Gold (GLD) | 39.8% | 27.0% | 1.22 | -1.5% |
| Commodities (DBC) | 50.6% | 18.0% | 2.21 | -0.8% |
| Real Estate (VNQ) | 13.0% | 13.5% | 0.66 | 10.1% |
| Bitcoin (BTCUSD) | -17.4% | 42.1% | -0.34 | 20.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GDRX | |
|---|---|---|---|---|
| GDRX | -39.7% | 73.0% | -0.37 | - |
| Sector ETF (XLV) | 4.9% | 14.6% | 0.16 | 25.5% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 40.3% |
| Gold (GLD) | 20.9% | 17.9% | 0.95 | 5.7% |
| Commodities (DBC) | 13.8% | 19.1% | 0.59 | 5.6% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 32.0% |
| Bitcoin (BTCUSD) | 7.0% | 56.0% | 0.34 | 22.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GDRX | |
|---|---|---|---|---|
| GDRX | -24.3% | 72.6% | -0.36 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 25.3% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 39.2% |
| Gold (GLD) | 13.4% | 15.9% | 0.69 | 5.2% |
| Commodities (DBC) | 9.3% | 17.8% | 0.44 | 6.0% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.24 | 30.4% |
| Bitcoin (BTCUSD) | 67.8% | 66.9% | 1.07 | 18.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | 10.5% | ||
| 2/25/2026 | -18.8% | -11.0% | -16.7% |
| 11/4/2025 | 2.1% | -7.1% | -16.9% |
| 8/6/2025 | -20.0% | -18.0% | -7.8% |
| 2/27/2025 | 1.8% | 1.0% | -7.6% |
| 11/7/2024 | -17.5% | -23.7% | -19.6% |
| 8/8/2024 | -18.6% | -20.4% | -10.5% |
| 5/9/2024 | -8.9% | -4.5% | 12.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 7 | 6 |
| # Negative | 13 | 13 | 14 |
| Median Positive | 3.2% | 4.0% | 13.1% |
| Median Negative | -18.6% | -15.6% | -16.6% |
| Max Positive | 20.4% | 17.0% | 37.1% |
| Max Negative | -38.9% | -47.5% | -33.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 5/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 765.00 Mil | 775.00 Mil | 785.00 Mil | 1.3% | Raised | Guidance: 765.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | 235.00 Mil | 2.2% | Raised | Guidance: 230.00 Mil for 2026 | |||
Prior: Q4 2025 Earnings Reported 2/25/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 750.00 Mil | 765.00 Mil | 780.00 Mil | ||||
| 2026 Adjusted EBITDA | 230.00 Mil | -14.8% | Lowered | Guidance: 270.00 Mil for 2025 | |||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Spectrum, Equity Vii, LP | Spectrum VII Investment Managers' Fund, L.P. | Sell | 10162025 | 4.00 | 15,202 | Form | |||
| 2 | Spectrum, Equity Vii, LP | Spectrum VII Co-Investment Fund L.P. | Sell | 10162025 | 4.00 | 8,569 | Form | |||
| 3 | Spectrum, Equity Vii, LP | Spectrum VII Investment Managers' Fund, L.P. | Sell | 9082025 | 4.05 | 10,243 | Form | |||
| 4 | Spectrum, Equity Vii, LP | Spectrum VII Co-Investment Fund L.P. | Sell | 9082025 | 4.05 | 5,773 | Form | |||
| 5 | Spectrum, Equity Vii, LP | Spectrum VII Investment Managers' Fund, L.P. | Sell | 7032025 | 4.80 | 6,828 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.